Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 slips as ex-dividend trades weigh, Rolls-Royce soars

Thu, 23rd Feb 2023 17:10

Rolls-Royce jumps on upbeat forecast

*

Major banks and healthcare stocks trade ex-div

*

FTSE 100 down 0.3%, FTSE 250 adds 0.6%

Feb 23 (Reuters) - The FTSE 100 ended lower on Thursday, as several banking and healthcare heavyweights traded ex-dividend, although shares of Rolls-Royce zoomed more than 20% after the aeroplane engine maker reported upbeat results.

The blue-chip index was down 0.3%, declining for a third straight session.

Shares of banks including Barclays and Standard Chartered and healthcare majors AstraZeneca and GSK slipped as they traded without entitlement for dividend payout.

Limiting losses on the FTSE 100 however Rolls-Royce surged 23.7% to post its biggest percentage gain in more than two years after the company's CEO forecast more profit growth in 2023.

"There was a lot of concern coming into this year generally about margins, results and (if) companies would be able to maintain their margins," said Caroline Simmons, UK chief investment officer at UBS Global Wealth Management.

"But what we've been seeing is so far the results have been broadly okay."

The FTSE 250 midcap index rose 0.6%, with John Wood Group Plc jumping 29.0% to the top of the index after the oilfield services and engineering firm said it received and rejected takeover proposals from Apollo Global Management.

Meanwhile, Bank of England interest rate-setter Catherine Mann said that it was

too soon to say

the risks posed by the surge in inflation last year had eased and that the central bank should continue to raise borrowing costs.

"Right now, the main driver for equities is just this reassessment of whether we have in fact priced peak rates, even if it means the recession is not coming," said Michael Metcalfe, head of macro strategy at State Street Global Markets.

Strong economic data in January has shaken investor confidence, he added.

Among other single stocks, Mondi fell 4.8% after the paper packaging company gave a cautious outlook.

Drax Group lost 3.7% as analysts said falling forward sales could hit the power generation firm's core earnings in 2024. The company posted annual profit that beat analysts' expectation. (Reporting by Shashwat Chauhan and Shristi Achar A in Bengaluru; editing by Uttaresh.V, Eileen Soreng and Andrew Heavens)

More News
16 Jun 2023 17:01

LONDON MARKET CLOSE: FTSE 100 ends a week of rate decisions higher

(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks.

Read more
16 Jun 2023 11:59

GSK cancer drug delay by FDA not "necessarily a red flag"

(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday.

Read more
16 Jun 2023 07:47

FDA extends review period of GSK blood cancer drug momelotinib

(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

Read more
16 Jun 2023 07:42

IN BRIEF: GSK says FDA extending review period for blood cancer drug

GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review."

Read more
9 Jun 2023 06:53

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

Read more
8 Jun 2023 12:09

London "still attractive" place to list, as IPO activity trickles back

(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended.

Read more
7 Jun 2023 09:22

EU approves its first vaccine for common respiratory virus RSV

June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.

Read more
7 Jun 2023 09:10

LONDON MARKET OPEN: Stocks head lower amid global growth fears

(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite.

Read more
7 Jun 2023 07:59

TOP NEWS: GSK's Arexvy is first EU-approved RSV jab for older adults

(Alliance News) - GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older.

Read more
7 Jun 2023 07:34

GSK gets European approval for RSV vaccine

(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.

Read more
6 Jun 2023 08:34

US FDA accepts GSK's licence application for cancer treatment Jemperli

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration accepted its supplemental biologics licence application for endometrial cancer treatment dostarlimab, or Jemperli, after it was granted priority review in September.

Read more
6 Jun 2023 07:41

PRESS: Unilever starts search to replace Nils Andersen as chair

(Alliance News) - Unilever PLC has appointed executive search firm Spencer Stuart to find a replacement for Chair Nils Andersen, Bloomberg reported on Monday, citing "people familiar with the situation".

Read more
6 Jun 2023 07:18

US FDA accepts GSK supplemental application for Jemperli cancer drug

(Sharecast News) - GSK said the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application for its Jemperli treatment of adults with primary advanced or recurrent endometrial cancer.

Read more
2 Jun 2023 21:42

IN THE KNOW: hVIVO involvement in drug approval should boost interest

(Alliance News) - hVIVO's involvement in the approval of pharmaceutical giant Pfizer's new vaccine Abrysvo should support interest in its services, according to Liberum.

Read more
31 May 2023 23:35

US FDA approves Pfizer's RSV vaccine

May 31 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.